



April 21, 2014

## ImmunoCellular Therapeutics Announces ICT-107 Phase II Data Abstract Accepted for Oral Presentation at the 2014 ASCO Annual Meeting

LOS ANGELES, April 21, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the abstract describing the Company's phase II trial of dendritic cell-based cancer vaccine ICT-107 in newly diagnosed glioblastoma (GBM) has been accepted for an oral presentation at the 2014 American Society for Clinical Oncology (ASCO) annual meeting, to be held in Chicago May 30-June 3, 2014.



The abstract accepted for oral presentation is titled, "A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients." The principal investigator on the study, Patrick Y. Wen, MD, Director, Center for Neuro-Oncology, Dana Farber Cancer Institute, and Professor Neurology, Harvard Medical School, will present during the session titled, Central Nervous System Tumors, on Sunday, June 1<sup>st</sup> at 8:00-11:00 am CT. Dr. Wen's presentation is scheduled for 10:00-10:12 am CT. The abstract number is 2005.

"We are honored that the ASCO Scientific Program Committee has selected our work in newly diagnosed GBM for oral presentation, typically reserved for important clinical and translational research findings," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We are looking forward to discussing the ICT-107 phase II results with key opinion leaders in the neuro-oncology community during, and in conjunction with, our presentation. We anticipate presenting updated overall survival results for both the whole trial population and key predefined sub-groups, as well as important immunological analyses that can provide insights relative to vaccine potency and response. This larger and richer data set will be the basis for informing our phase III design and execution strategies. We look forward to Dr. Wen's presentation, and want to express our sincere appreciation for the ongoing interest and support within the neuro-oncology community for ICT-107's continued development."

### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

### Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Logo - <http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO>

Contact:

ImmunoCellular Therapeutics, Ltd.  
Investor Relations  
Jane Green  
415.348.0010 direct  
415.652.4819 mobile  
[jane@jmgcomm.com](mailto:jane@jmgcomm.com)

SOURCE ImmunoCellular Therapeutics, Ltd.

